trulicity a glp 1 Lawsuit - July 2026 Update Trulicity (dulaglutide): Injectable GLP-1 RA

transient impairment of glucose tolerance is possible, particularly in individuals with pre-existing insulin resistance Injection site reactions: Mild and typically localised Contraindications include active malignancy (GH-IGF-1 signalling can promote tumour growth), pituitary-dependent conditions, pregnancy, and active diabetic retinopathy

The findings are interesting

This research received funding from CNPq (Fluid Complex INCT) and Sao Paulo Research Foundation (Fapesp) under grant agreement nos 2014/06992-8, 2012/02270-2 and 2013/07937-8

According to the data administering 500 mg/kg of this substance in rats has shown an antidiabetic effect, attributable to berberine, which enhances insulin production and stimulates glycolysis